Genmab (GMAB) Q4 2025 earnings review
Royalties Boom, But Transition Costs Crush Margins
Genmab is aggressively maneuvering to become a fully integrated commercial biotech, but the transition carries a heavy price tag. FY25 Revenue grew 19% to $3.72B, fueled by an unstoppable $2.4B royalty stream from DARZALEX. However, the bottom line tells a completely different story. Q4 Net Income collapsed 94% YoY to just $31M, dragging full-year Net Income down 15%. This sudden compression was triggered by the $8B acquisition of Merus, which brought $185M in immediate charges, liquidated the company's entire marketable securities portfolio, and strapped the balance sheet with $5.5B in new debt. Management's 2026 guidance confirms this is an investment phase: while revenue is expected to grow ~14%, operating expenses will surge by 26% to $2.8B, pushing expected operating profit into a decline.
🐂 Bull Case
J&J's DARZALEX sales grew 23% to $14.35B, generating $2.44B in pure royalty profit for Genmab. This high-margin recurring revenue flawlessly funds the company's aggressive R&D and M&A pipeline without requiring dilutive equity raises.
Genmab's own commercial engines are firing. Combined proprietary sales for EPKINLY and Tivdak reached $632M, up 54% YoY. The recent launch of EPKINLY in 2L Follicular Lymphoma opens access to a ~9,000 patient market in the community setting.
🐻 Bear Case
The pivot to an integrated model is ravaging margins. 2026 Operating Expenses are guided to $2.81B (midpoint)—a 26% leap over 2025's adjusted $2.22B. Consequently, Operating Profit will actually reverse and decline by ~9% next year.
Despite management calling EPKINLY a 'core therapy,' the Phase 3 DLBCL-1 monotherapy trial explicitly missed its Overall Survival (OS) endpoint. This complicates the regulatory narrative and gives competitors an opening.
⚖️ Verdict: ⚪
Neutral. Genmab possesses one of the best royalty engines in biotech, but the aggressive M&A and R&D spend means earnings growth is officially paused. The stock will trade entirely on clinical execution of Rina-S and petosemtamab, not near-term EPS.
Key Themes
EPCORE DLBCL-1 Misses Overall Survival Endpoint
A notable crack appeared in the EPKINLY narrative. Management reported that the Phase 3 EPCORE DLBCL-1 monotherapy trial failed to reach statistical significance on Overall Survival (OS), despite beating the chemo-immuno regimen on Progression-Free Survival (PFS). While management attributed the miss to the Omicron wave and crossover access to other bispecifics, this data point directly contradicts their flawless 'best-in-class' messaging and will require careful negotiation with global health authorities to avoid labeling restrictions.
Petosemtamab Transforms the Pipeline
Accelerating. The $8B acquisition of Merus brings petosemtamab (Peto) into the fold. This EGFRxLGR5 bispecific is a potential first-in-class asset with two FDA Breakthrough Therapy Designations. In 1L Head and Neck cancer, it achieved a 63% response rate with pembro (vs 19% standard of care). Genmab expects one or both Phase 3 trials to read out in late 2026, setting up a massive 2027 launch.
Margin Squeeze from Soaring OpEx
Reversing. Genmab is heavily sacrificing near-term profitability to build its future. Operating expenses (adjusted for one-offs) grew 13% in 2025 but are guided to explode by ~26% in 2026 to $2.81B at the midpoint. This scale-up is required to run multiple Phase 3 trials for Peto and Rina-S, alongside global commercial build-outs. The result is a guided drop in operating profit for 2026.
Rina-S Rewriting the ADC Playbook
Accelerating. Rina-S (acquired via ProfoundBio) is proving to be a 'pipeline-in-a-product.' Because it works irrespective of folate receptor alpha expression levels, it effectively triples the addressable patient population compared to existing high-expresser ADCs. Genmab is aggressively initiating three Phase 3 trials across ovarian and endometrial cancers, targeting a 2027 launch.
Debt-Fueled M&A in Favorable Macro Environment
Reversing. Genmab’s capital structure has fundamentally changed. Entering the year with $2.9B in liquidity and zero debt, the company liquidated its entire $1.57B marketable securities portfolio and took on $5.5B in debt (at an effective rate of ~6.6%) to acquire Merus. Management cited the macro environment as 'excellent' for acquiring capital-constrained biotechs. They target deleveraging below 3x by 2027.
Platform Discontinuations Highlight R&D Risks
Stable. The inherent risk of oncology R&D was evident as Genmab discontinued two major programs: acasunlimab (GEN1046) in Q4 after BioNTech opted out, and the HexaBody-OX40 program. The acasunlimab termination triggered $57M in specific termination costs. While management framed this as 'disciplined portfolio prioritization,' it raises questions about the internal productivity of the HexaBody platform.
Other KPIs
Accelerating. Up 57% from $253M in 2024. This line item represents Genmab's shift to an integrated commercial model, driven primarily by EPKINLY sales in the US and Japan, and the new independent rollout of Tivdak in Germany and Japan.
Accelerating. Up from $291M in 2024, but the composition is shifting drastically. Going forward, this line will carry the weight of $5.5B in new debt at ~6.6% interest, drastically altering the company's previously pristine zero-debt profile.
Guidance
Decelerating. The midpoint of $4.23B implies 14% YoY growth, a slight step down from the 19% growth achieved in 2025. This is anchored by an expected $2.7B in DARZALEX royalties.
Accelerating. A massive leap from 2025's adjusted $2.22B. This ~26% growth drastically outpaces revenue growth, entirely driven by late-stage trials for Rina-S and petosemtamab, plus global launch readiness.
Reversing. The $1.15B midpoint implies a ~9% decline from 2025's adjusted operating profit of $1.26B. The company is actively sacrificing current earnings to fund its transition to a 100% owned portfolio.
Key Questions
Regulatory Path for EPKINLY Post-OS Miss
Given the Overall Survival miss on the EPCORE DLBCL-1 trial, how does this specifically alter your regulatory conversations with the FDA regarding monotherapy labels, and does it put increased pressure on the upcoming combo trials?
Peak OpEx and Margin Trough
With 2026 operating expenses jumping 26% to $2.8B, should investors view 2026 as the 'trough' year for operating margins, or will R&D intensity continue to outpace revenue into 2027 ahead of the Rina-S/Peto launches?
Debt Capacity and Future M&A
You noted the macro environment is 'excellent' for acquiring assets from cash-constrained biotechs. Having just taken on $5.5B in debt, how much dry powder remains for BD, and would you consider equity dilution to fund further opportunistic deals?
Platform Productivity
With the discontinuation of acasunlimab and the HexaBody-OX40 program, how are you evaluating the internal ROI of the early-stage pipeline versus buying de-risked assets externally like Merus and ProfoundBio?